Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa
Pim Aarts, Koen Dudink, Allard R.J.V. Vossen, et al.
Drugs (2021) Vol. 81, Iss. 12, pp. 1397-1410
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

New and Emerging Targeted Therapies for Hidradenitis Suppurativa
Adela Markota Čagalj, Branka Marinović, Zrinka Bukvić Mokoš
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3753-3753
Open Access | Times Cited: 52
Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies
Stephanie L Schell, Zhaoyuan Cong, Mackenzie L. Sennett, et al.
British Journal of Dermatology (2022) Vol. 188, Iss. 3, pp. 407-419
Closed Access | Times Cited: 39
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial
Alexa B. Kimball, Errol P. Prens, Thierry Passeron, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 5, pp. 1099-1111
Open Access | Times Cited: 37
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
Fabrizio Martora, Massimiliano Scalvenzi, Angelo Ruggiero, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 801-801
Open Access | Times Cited: 36
Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting
Pim Aarts, Johanna C. van Huijstee, Hessel H. van der Zee, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 4, pp. 677-684
Open Access | Times Cited: 27
Guselkumab for the treatment of patients with moderate‐to‐severe hidradenitis suppurativa: A phase 2 randomized study
Alexa B. Kimball, Maurizio Podda, Afsáneh Alavi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 10, pp. 2098-2108
Open Access | Times Cited: 25
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa
Alexa B. Kimball, Elena Peeva, Seth Forman, et al.
NEJM Evidence (2024) Vol. 3, Iss. 3
Closed Access | Times Cited: 13
Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues
Elisa Molinelli, Edoardo De Simoni, Matteo Candelora, et al.
Antibiotics (2023) Vol. 12, Iss. 6, pp. 978-978
Open Access | Times Cited: 21
Association between hidradenitis suppurativa and atopic diseases: a multi-center, propensity-score-matched cohort study
Hui‐Chin Chang, Chenyu Lin, Yuchen Guo, et al.
International Journal of Medical Sciences (2023) Vol. 21, Iss. 2, pp. 299-305
Open Access | Times Cited: 17
Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease
Margaret Y. Huang, April W. Armstrong
Indian Journal of Dermatology Venereology and Leprology (2023) Vol. 90, pp. 30-40
Open Access | Times Cited: 16
The Role of IL-17 in Systemic Autoinflammatory Diseases: Mechanisms and Therapeutic Perspectives
Jingyuan Zhang, Min Shen
Clinical Reviews in Allergy & Immunology (2025) Vol. 68, Iss. 1
Closed Access
Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis
Ya‐Chu Tsai, Chen‐Yiu Hung, Tsen‐Fang Tsai
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1351-1351
Open Access | Times Cited: 15
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa
Elisa Molinelli, Helena Gioacchini, Claudia Sapigni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8428-8428
Open Access | Times Cited: 14
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?
Edinson López, Raúl Cabrera, Cristóbal Lecaros
Anais Brasileiros de Dermatologia (2024) Vol. 99, Iss. 4, pp. 546-567
Open Access | Times Cited: 3
Targeting mitochondria in dermatological therapy: beyond oxidative damage and skin aging
Tongyu C. Wikramanayake, Jérémy Chéret, Alec Sevilla, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 3, pp. 233-259
Open Access | Times Cited: 17
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies
Natalie M Fragoso, Rahul Masson, Justin Gillenwater, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 8, pp. 1661-1697
Open Access | Times Cited: 10
Outcomes and Reliability of Perforator Flaps in the Reconstruction of Hidradenitis Suppurativa Defects: A Systemic Review and Meta-Analysis
Camille Vaillant, Yanis Berkane, Elise Lupon, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 19, pp. 5813-5813
Open Access | Times Cited: 13
Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe
D. Willems, Eva-Lotta Hinzpeter, Hessel H. van der Zee, et al.
Patient (2023) Vol. 16, Iss. 2, pp. 153-164
Open Access | Times Cited: 7
Hidradenitis suppurativa as a potential risk factor of periodontitis: a multi-center, propensity-score-matched cohort study
Shuo‐Yan Gau, Yuchen Guo, Hsin-Yo Lu, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 5, pp. 874-881
Open Access | Times Cited: 2
Inflammasomes: emerging therapeutic targets in hidradenitis suppurativa?
Ciara Campbell, Jay M Mayatra, Ashish Neve, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 5, pp. 670-679
Open Access | Times Cited: 2
Bimekizumab in hidradenitis suppurativa: a valid and effective emerging treatment
Elisa Molinelli, Daisy Gambini, Andrea Maurizi, et al.
Clinical and Experimental Dermatology (2023) Vol. 48, Iss. 11, pp. 1272-1274
Closed Access | Times Cited: 6
Disease Burden and Treatment Patterns Among US Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study
Amit Garg, Yvonne Geissbühler, Emma Houchen, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 6, pp. 977-990
Open Access | Times Cited: 5
New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review
Keiichi Yamanaka
The Journal of Dermatology (2023) Vol. 51, Iss. 2, pp. 172-179
Open Access | Times Cited: 5
Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa
Aikaterini Tsiogka, Aikaterini I. Liakou, Efthimia Agiasofitou, et al.
Dermatology (2023) Vol. 239, Iss. 6, pp. 937-941
Closed Access | Times Cited: 4
Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa
Rene Chen, Robyn Guo, Amy J. Petty, et al.
Immuno (2024) Vol. 4, Iss. 1, pp. 57-76
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top